TriSalus Execs to Present at H.C. Wainwright Conference
Event summary
- TriSalus CEO Mary Szela and CFO David Patience to participate in H.C. Wainwright conference Sept. 14-15, 2026.
- Fireside chat scheduled for Sept. 14 at 5:00 p.m. ET.
- Webcast replay available for 90 days post-event.
- Company focuses on oncology with proprietary drug delivery tech and nelitolimod immunotherapy.
- Two FDA-cleared devices: TriNav Infusion System and Pancreatic Retrograde Venous Infusion System.
The big picture
TriSalus' participation in the H.C. Wainwright conference comes as the company advances its proprietary drug delivery technology and immunotherapy. The event provides a platform to showcase its FDA-cleared devices and clinical-stage assets to potential partners and investors. The oncology sector continues to prioritize innovative delivery mechanisms to improve treatment outcomes for solid tumors, making TriSalus' technology particularly relevant.
What we're watching
- Clinical Progress
- The pace at which TriSalus completes phase 1 trials and explores partnerships for nelitolimod.
- Technology Adoption
- How the company's Pressure-Enabled Drug Delivery approach will affect market penetration.
- Investor Sentiment
- Whether the conference presentations will shift perceptions of TriSalus' growth trajectory.
Related topics